Market Flux Event

Erasca Reports Strong ERAS-0015 Response Rates in KRAS-Mutant Pancreatic Cancer as United Therapeutics Completes First Xenokidney Transplant

Read this in the Market Flux app

Erasca released updated Phase 1 data on November 20 for ERAS-0015, its oral pan-RAS molecular glue, showing high confirmed objective response rates in patients with KRAS-mutant pancreatic ductal adenocarcinoma. At the 32 mg once-daily dose in the AURORAS-1 trial, the drug achieved a 44% confirmed overall response rate in second-line or later KRAS G12X PDAC patients, a population with heavy prior treatment (84% in the third-line or later setting) and a high share of harder-to-treat G12R mutations at 44% of patients. Among those with KRAS G12D or G12V mutations, which together account for nearly 70% of all PDAC cases, the confirmed ORR rose to 69%, including 63% in G12D and 80% in G12V patients.

Erasca also disclosed Phase 1 data for ERAS-4001, a potential first-in-class pan-KRAS inhibitor. Preclinical data show the combination of ERAS-0015 and ERAS-4001 targets both active- and inactive-state KRAS with synergistic activity in KRAS G12X-driven models, supporting planned combination trials in 2027. The company said the full dataset supports further development in first-line PDAC.

In a separate clinical milestone, United Therapeutics announced the first transplant in its EXTEND trial of the UThymoKidney, a genetically engineered pig kidney, performed at NYU Langone Health. The study targets patients with end-stage renal disease who are ineligible for conventional kidney transplantation. Also on November 20, Merck's TroFuse-015 trial evaluating sacituzumab tirumotecan met its primary endpoint of overall survival in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. Immutep separately reported 81.1% 12-month disease-free survival from its EFTISARC-NEO Phase II study of eftilagimod alfa combined with pembrolizumab and radiotherapy as neoadjuvant treatment in 40 patients with high-risk resectable soft tissue sarcoma.

© AI-generated summary is provided by Market Flux

Sources

  1. NasdaqAlterity Therapeutics Limited Reports FDA Alignment on Phase 3 Trial Design and A$41.3 million Cash Balance
  2. BioStocks$MRK TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoint of OS in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
  3. Business WireUnited Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease
  4. InvestingErasca reports updated Phase 1 data for ERAS-0015 and ERAS-4001 in solid tumors
  5. ReutersMerck's drug prolongs survival in advanced stomach, esophageal cancers in trial
  6. MarketsdayMerck $MRK TroFuse-015 Phase 3 Trial Meets Overall Survival but Misses Progression-Free Survival - November 20, 2026 🔹 Merck $MRK announced that its global Phase 3 TroFuse-015 trial met its primary endpoint of overall survival for sacituzumab tirumotecan versus treatment of physician's choice in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. 🔹 The TROP2-directed antibody-drug conjugate did not meet its secondary progression-free survival endpoint as assessed by blinded independent central review, while objective response rates nominally favored sacituzumab tirumotecan without formal statistical testing under the prespecified plan. 🔹 Merck $MRK noted no new safety signals were observed, with the safety profile remaining consistent with prior studies of sacituzumab tirumotecan, which is licensed from Kelun-Biotech outside Greater China. 🔹 TroFuse-015 marks the first overall survival benefit in a global Phase 3 study for a TROP2-directed antibody-drug conjugate in this setting and the second positive Phase 3 readout across Merck $MRK's 18-trial TroFuse program, which plans to share full findings at a medical meeting and engage regulators. #Merck #MRK #Oncology #ClinicalTrials #ADC #Biopharma #StockMarket
  7. Seeking AlphaBambusa Therapeutics: Compelling Early Data Doesn't Justify The Current Premium
  8. TheTradeXchange$NCNA - NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium